DaVita (NYSE:DVA) Releases FY 2024 Earnings Guidance

DaVita (NYSE:DVA) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share guidance of 9.250-10.050 for the period, compared to the consensus earnings per share estimate of 9.790. The company issued revenue guidance of -. DaVita also updated its FY24 guidance to $9.25-$10.05 EPS.

DaVita Stock Performance

DaVita stock traded up $1.27 during mid-day trading on Tuesday, reaching $158.32. The company’s stock had a trading volume of 1,266,738 shares, compared to its average volume of 805,333. The company has a market capitalization of $13.28 billion, a P/E ratio of 16.86, a PEG ratio of 0.90 and a beta of 0.87. The firm’s fifty day moving average price is $158.40 and its two-hundred day moving average price is $146.05. DaVita has a 12-month low of $75.47 and a 12-month high of $168.50. The company has a debt-to-equity ratio of 9.94, a quick ratio of 1.12 and a current ratio of 1.16.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.47 by $0.12. The business had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.15 billion. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.08 EPS. Sell-side analysts predict that DaVita will post 9.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Truist Financial increased their target price on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. UBS Group lifted their price objective on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. TD Cowen upped their target price on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Finally, Bank of America boosted their price objective on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $159.00.

Insider Buying and Selling at DaVita

In other news, COO Michael David Staffieri sold 9,539 shares of the stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the transaction, the chief operating officer now directly owns 241,945 shares in the company, valued at approximately $36,299,008.35. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, COO Michael David Staffieri sold 9,539 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the sale, the chief operating officer now directly owns 241,945 shares in the company, valued at approximately $36,299,008.35. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares in the company, valued at approximately $12,137,038.31. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 173,482 shares of company stock worth $27,387,069 over the last 90 days. Corporate insiders own 2.00% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.